Ensysce Biosciences faces Nasdaq delisting risk over $2.5 million equity shortfall

• Nasdaq issued a notice on May 21, 2026, citing non-compliance with the $2.5 million stockholders’ equity requirement under Listing Rule 5550(b)(1) as of March 31, 2026.
• Delisting risk unless a compliance plan is submitted within 45 days, due by July 6, 2026.
• Acceptance of the plan could allow up to a 180-day extension from May 21, 2026, to regain compliance.
• Rejection would shift the process to an appeal to the Nasdaq Hearings Panel.
• Management plans to submit a plan on time while exploring options to restore compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-025061), on May 22, 2026, and is solely responsible for the information contained therein.